Trend-Following Backtester · Guide · backtest 한국어

equity · NZ

Ryman Healthcare Ltd. backtest

10 trend-following strategies were compared on the full daily history of Ryman Healthcare Ltd.. 6 beat buy-and-hold CAGR; EMA 크로스오버 ranks first by Sharpe, matching the main backtester. The return/drawdown alternative is 볼린저 밴드 돌파 (CAGR 7.0%, MDD -32.0%).

Data 2000-01-04 ~ 2026-07-30daily bars 6,720 (26.6 years)Costs 0.5%Venue NZXMonthly snapshot 2026-07-31

Results by strategy

6 of 10 beat buy and hold (CAGR 6.3%, drawdown -87.7%).

Sharpe leader (same as main): EMA 크로스오버 — CAGR 11.9%, MDD -39.6%, Sharpe 0.72, 60% exposure.

Return/drawdown alternative: 볼린저 밴드 돌파 — CAGR is 5.7%p higher than buy and hold, while drawdown improves by 48.1%p (CAGR 7.0%, MDD -32.0%, exposure 33%).

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
EMA 크로스오버
fast=25, slow=82
11.9%-39.6%0.720.3020.0x5460%
SMA 크로스오버
fast=10, slow=130
11.7%-51.0%0.700.2318.8x6661%
Keltner 채널 돌파
emaPeriod=112, atrPeriod=14, mult=2.4
10.2%-43.7%0.690.2313.4x7452%
Donchian 채널 돌파
entryN=86, exitN=46
10.0%-37.1%0.680.2712.4x4651%
ADX / DI 방향성
period=27, threshold=26
5.6%-24.6%0.620.234.3x5818%
볼린저 밴드 돌파
n=48, k=2.3
7.0%-32.0%0.580.226.1x8833%
ROC 모멘텀
n=139, threshold=0.12
6.3%-56.2%0.510.115.0x17040%
Supertrend
period=8, mult=4.6
6.0%-52.1%0.420.124.7x12859%
MACD
fast=31, slow=56, signal=31
4.3%-42.4%0.320.103.1x16951%
Parabolic SAR
step=0.015, maxStep=0.3
2.0%-57.0%0.200.031.7x38152%
Buy and hold6.3%-87.7%0.360.075.0x1100%
1x 10x 2001 2005 2009 2013 2017 2021 2025 EMA 크로스오버Buy and hold
EMA 크로스오버: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -22% -44% -66% -88% 2001 2005 2009 2013 2017 2021 2025 Buy and holdEMA 크로스오버
EMA 크로스오버 maximum drawdown -39.6% (2019-12-29 → 2026-02-15), prior peak not yet recovered.

Rules of the top strategy

Uses two exponential averages (more weight on recent prices) and trades their crossover.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupAll asset reports

Read next